Search results for: Diego Ossa
Filter search results
Our Contributions to the Economics of Personalised Medicine
7 March 2018
…Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2013). Can and should value-based pricing be applied to molecular diagnostics? Personalized Medicine. 10(1), 61-72. DOI Innovations in…
Dr. Inmaculada Hernandez
3 September 2024
Dr. Inmaculada (Inma) Hernandez is a Professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Hernandez is a pharmacist and a scholar whose…
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
1 May 2012
…at launch, review would be by a diagnostics-dedicated committee using VBP principles. Download Garau, M., Towse, A., Garrison, L., Housman L. and Ossa, D. Can and should value based pricing…
Valuing Co-Dependent Medical Technologies: Improving Methods and Processes
23 April 2013
…information, please contact Martina Garau. See also: Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2012) Can and should value based pricing be applied to molecular diagnostics?…
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
…Adrian Towse from Office of Health Economics Related OHE publications and materials include the following. Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2013) Can and should…
OHE Involved in Developing New AMS Report on Stratified Medicines
15 July 2013
…M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2013) Can and should value-based pricing be applied to molecular diagnostics? Personalized Medicine. 10(1), 61-72. An earlier version is available…
Personalised Medicine: Economic Incentives for Evidence Generation
28 October 2013
…the AMS website. Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2013) Can and should value-based pricing be applied to molecular diagnostics? Personalized Medicine. 10(1), 61-72. An earlier…
Personalised Medicine and the Value of Molecular Diagnostics: Case Studies
18 December 2013
…and the public sector should help fund research on the clinical effectiveness of molecular diagnostics. [1]Open access: Towse, A., Ossa, D., Veenstra, D., Carlson, J. and Garrison, L. (2013) Understanding…